United States Patent 11,680,058: Scope, Claim Coverage, and US Patent Estate for Crystalline {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide
What is US Patent 11,680,058 claiming in plain scope terms?
Core claim theme: treatment methods that use a specific crystalline polymorph of a defined sulfonamide compound, where the polymorph is identified by X-ray powder diffraction (XRPD) peak positions under a defined measurement protocol.
Main compound definition (repeated throughout):
{5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide.
Main polymorph definition (repeated throughout, with two XRPD “peak sets”):
A crystalline form is characterized by either:
- XRPD Peak Set A: peaks at 2θ = 17.8°, 18.6°, 20.0°, 23.2°, 23.5°, or
- XRPD Peak Set B: peaks at 2θ = 7.8°, 9.7°, 15.7°, 19.8°, 22.0°
Measurement protocol constraints:
- XRPD obtained using combined Cu Kα1 and Kα2 radiation
- without Kα2 stripping
- accuracy of 2θ values is ±0.2°
Claim coverage structure:
- Broad method-of-treatment independent claim (claim 1) with an extensive disease list.
- Subsequent claim sets narrow by indication and by dosage form/composition.
- Dependent claims add CKD stage definitions, diabetic sub-indications, hypertension sub-types, and unit dose / formulation ranges.
Active-ingredient boundary and what “crystalline form” does
The claims are not written as “the compound” per se. They are written as methods that require administering an “identified crystalline form” that matches the XRPD criteria above. That creates two practical design-around options for competitors:
- market a different crystalline form/polymorph not matching the XRPD peak criteria, or
- match the XRPD criteria but use a formulation/dosage regimen outside the claimed ranges (for claims that recite those ranges).
The strongest infringement hook is claim 1’s combination of:
(i) disease treatment + (ii) administering + (iii) the polymorph identified by XRPD.
How broad are the treatment indications in claim 1 and claims 2–3?
Claim 1: expansive indication list (highest risk of generic/non-infringing crossover)
Claim 1 covers methods for treating:
- hypertension
- pulmonary hypertension
- coronary disease
- cardiac insufficiency
- renal ischemia
- myocardial ischemia
- renal failure
- cerebral ischemia
- dementia
- migraine
- subarachnoidal hemorrhage
- Raynaud’s syndrome
- digital ulcers
- portal hypertension
- chronic kidney disease (CKD)
Infringement trigger: administering the defined XRPD-characterized crystalline sulfonamide polymorph in an “effective amount.”
Claim 2: CKD and cardio-metabolic cluster + diabetic microvascular disease
Claim 2 covers:
- chronic kidney disease (CKD)
- diabetes
- diabetic nephropathy
- diabetic retinopathy
- diabetic vasculopathy
- chronic heart failure
- diastolic dysfunction
Claim 3: overlaps major cardiovascular-renal indications with a narrower set than claim 1
Claim 3 covers:
- hypertension
- heart failure
- chronic kidney disease (CKD)
Dependent indication narrowing (claims 4–10)
- Claim 4: hypertension (as a specialization of claim 1)
- Claim 5: essential hypertension, resistant hypertension, pulmonary hypertension, pulmonary arterial hypertension
- Claim 6: essential hypertension or resistant hypertension (subset)
- Claim 8: CKD stages 1 to 4 (KDIGO) where CKD is caused by essential hypertension
- Claim 9: diabetic nephropathy
- Claim 10: chronic heart failure
Practical read: The independent claim set already spans the cardiovascular-renal field broadly. Dependent claims add narrower, higher-value positions that can matter in litigation when the clinical label/marketing claims track a specific sub-indication (e.g., CKD stages 1–4 caused by essential hypertension).
What is the XRPD polymorph scope and how many “peak-set variants” are protected?
The claim grammar creates two alternative XRPD identifiers
Across claims 1–3 and multiple dependents, the crystalline form can be characterized by either of two XRPD peak sets:
Peak Set A (5 peaks):
- 17.8°, 18.6°, 20.0°, 23.2°, 23.5°
Peak Set B (5 peaks):
- 7.8°, 9.7°, 15.7°, 19.8°, 22.0°
XRPD instrument and analysis constraints matter for infringement
- Combined Cu Kα1 and Kα2 radiation
- No Kα2 stripping
- 2θ accuracy ±0.2°
Design-around leverage: A competitor can target a polymorph with different dominant peaks or different indexing such that it does not satisfy the required peak positions under the specified XRPD conditions. The claims also leave room for “other peaks” to exist; they require the presence of specified peaks, not the absence of others.
Claims that explicitly anchor to FIG. 1
- Claim 16: the crystalline form “essentially shows” the XRPD pattern as depicted in FIG. 1 (dependent on claim 6).
This adds evidentiary/interpretation leverage: in litigation, FIG. 1 can become a comparator for whether the accused material is “essentially” the same polymorph as the claimed one.
What dosage, unit amount, and solid composition ranges are claimed?
Unit dose range (claim 17)
- administered in unit dosage form suitable for oral administration of 10 to 50 mg per day of the sulfonamide.
This is a dosing-limitation dependent claim under the claim 6 indication scope (essential/resistant hypertension).
Solid dosage composition ranges (claims 18–21)
Claim 18: solid pharmaceutical composition with component ranges (by weight % of total composition):
- crystalline sulfonamide: 5–25%
- microcrystalline cellulose: 20–30%
- lactose: 40–65%
- hydroxypropylcellulose: 1–3%
- croscarmellose sodium: 2–8%
- magnesium stearate: 0.2–2%
Claim 19: composition is a tablet.
Claims 20–21: repeat the claim 18 composition ranges and constrain to:
- unit dosage form includes the crystalline polymorph with XRPD criteria
- solid form is tablet
Practical risk point: If an accused product uses a different excipient system, the method claims without formulation recitations may still be asserted (claim 1–3 are not excipient-limited). But for a product featuring those exact excipient ranges and dosage form, these dependent formulation claims add a stronger parallel infringement lane.
Which claims add the most litigation leverage?
Highest leverage claim families
-
XRPD-constrained treatment methods (claims 1–3)
These likely carry the broadest infringement reach across diseases that the commercial product label might cover.
-
Indication-specific narrowing (claims 4–10, 16–17)
These matter when the clinical use is targeted to essential/resistant hypertension, pulmonary arterial/pulmonary hypertension, CKD stages 1–4 caused by essential hypertension, diabetic nephropathy, or chronic heart failure.
-
Dosage form and composition claims (claims 17–21)
These matter for formulation and product presentation evidence, especially if accused generics attempt to keep the same indication while changing only excipients.
Claims 11–15: XRPD details embedded into the dependent limitation chain
- Claim 11–14: recite the Peak Set A variant (17.8°, 18.6°, 20.0°, 23.2°, 23.5°) with the same measurement protocol.
- Claim 15: introduces an expanded peak list (9.8°, 9.9°, 11.7°, plus the Peak Set A peaks and additional 21.5°, 22.8° and 23.5°) under the XRPD criteria; dependent on claim 6.
Implication: claim 15 suggests there is a particular “essential hypertension/resistant hypertension” tied material signature with additional observed peaks. It can support arguments that multiple XRPD patterns correspond to the claimed crystalline form, or that FIG. 1 and the additional peak list define a more specific polymorph fingerprint.
How does US 11,680,058 compare with typical “crystalline form” patent strategies?
Claim focus is polymorph identity plus therapeutic method
In “crystalline form” IP strategies, the typical landscape splits into:
- composition/polymorph claims (material)
- method-of-treatment claims (clinical)
- formulation claims (tablet/excipients)
US 11,680,058 is heavy on method-of-treatment with polymorph identity, then extends to unit dose and solid formulation via dependents.
Why this matters for market exclusivity and generic entry risk
Even if a generic finds a polymorph that avoids the XRPD peak-set tests, the patent’s claim coverage still pushes risk analysis toward:
- whether the generic’s API polymorph is actually outside the XRPD criteria under the specified Cu radiation/no stripping method
- whether product label indications fall within the claimed disease list
- whether formulation and dose ranges fall within the dependent claim constraints
What patent estate gaps are implied by only having this single patent’s claim text?
No other claims, specification, priority data, or continuation families are provided here. As a result, this analysis cannot map:
- whether there are earlier US, PCT, or EP counterparts with broader “composition of matter” claims
- whether there are separate “salt” or “hydrate” patents
- whether there is an FDA Orange Book listing tied to this patent number
- whether other patents in the same family cover intermediate processes or specific manufacturing steps
Per constraint, only the provided claims are used to determine scope.
Key Takeaways
- US 11,680,058 is a method-of-treatment patent built around a specific XRPD-defined crystalline polymorph of a brominated pyrimidine sulfonamide.
- Claim 1 is the broadest hook: it covers treatment of a wide set of cardiovascular-renal and CNS indications using the XRPD-characterized crystalline form.
- XRPD criteria are central: infringement depends on matching specified 2θ peak positions (±0.2°) using Cu Kα1+Kα2 without Kα2 stripping.
- Dependent claims tighten to high-value clinical labels (essential/resistant hypertension, pulmonary hypertension categories, CKD KDIGO 1–4 caused by essential hypertension, diabetic nephropathy, chronic heart failure).
- Some dependent claims add product-level constraints for oral dosing (10–50 mg/day) and for solid tablet formulations with specific excipient weight ranges.
FAQs
1) Does US 11,680,058 cover any crystalline form of the sulfonamide?
No. The claims require a crystalline form characterized by specified XRPD peak positions under defined Cu radiation and no Kα2 stripping.
2) What are the two XRPD peak sets used to define the crystalline form?
Peak Set A: 17.8°, 18.6°, 20.0°, 23.2°, 23.5°. Peak Set B: 7.8°, 9.7°, 15.7°, 19.8°, 22.0°.
3) Are hypertension subtypes covered even if the indication is narrower than “hypertension”?
Yes. Dependent claims cover essential and resistant hypertension, and also pulmonary hypertension and pulmonary arterial hypertension.
4) Do the dependent claims restrict tablet composition?
Yes. Claims 18–21 recite weight % ranges for crystalline API, microcrystalline cellulose, lactose, hydroxypropylcellulose, croscarmellose sodium, and magnesium stearate, and specify tablet form.
5) If a generic changes excipients, does it avoid infringement?
Not from claim 1–3 alone, since those are not excipient-limited. Excipients matter mainly for dependent formulation claims (claims 18–21).
References
No external sources were cited because only the provided claim text for US 11,680,058 was used.
